# Hyperkalemia: Recognize, Stabilize, Shift, Remove, Reassess

## Recognize risk before choosing a treatment

Hyperkalemia can cause lethal conduction disturbance. Assess symptoms, the potassium concentration and trend, kidney function, the clinical setting, and the ECG. A normal ECG does not reliably exclude danger. Severe hyperkalemia, concerning ECG changes, or clinical instability requires urgent monitored assessment \[1,2\].

Check for sampling artifact when appropriate, but do not delay treatment of a convincing emergency while awaiting a repeat sample. Hemolysis, difficult collection, or marked blood-cell abnormalities can produce misleading results. Interpret laboratory and point-of-care results in context \[1,3\].

## Find the mechanism and reversible contributors

Consider impaired kidney excretion, reduced distal sodium delivery or aldosterone effect, cellular potassium release, and shifts out of cells. Review potassium supplements, salt substitutes, renin-angiotensin system drugs, potassium-sparing diuretics, NSAIDs, trimethoprim, and other relevant exposures \[2\].

AKI, advanced CKD, tissue injury, and insulin deficiency can coexist. Dietary intake alone is rarely the complete explanation when kidney handling is impaired. Treat the cause and reconsider long-term medication plans after immediate danger is controlled.

## Protect the myocardium when indicated

Intravenous calcium is used for hyperkalemia-associated ECG changes or other indications defined by the emergency protocol. Calcium stabilizes the myocardium; it does not remove potassium. Reassess the ECG and clinical response, and follow local formulation, administration, and repeat-dose guidance \[1,3\].

Stabilization, potassium shifting, removal, and cause assessment may need to proceed in parallel. A rigid sequence that delays emergency treatment for a bladder catheter is unsafe.

## Shift potassium into cells and monitor glucose

Insulin with appropriate glucose support temporarily shifts potassium into cells. Monitor glucose before and repeatedly after treatment because hypoglycemia can be delayed, particularly with kidney impairment. Nebulized beta-2 agonists can provide an additional shift, but response varies and they should not be relied on alone for severe hyperkalemia \[1,3\].

Bicarbonate is not a reliable stand-alone potassium treatment in every patient. Its role depends on acid-base status, sodium load, and the clinical setting. Do not predict a fixed potassium change from a change in pH \[3\].

## Arrange potassium removal

| Strategy | When it may help | Limitation |
|----|----|----|
| Urinary excretion, sometimes supported by a loop diuretic | Residual kidney function and an appropriate volume/perfusion context | Response is uncertain in severe AKI or oliguria |
| Gastrointestinal potassium binders | Selected adjunctive or ongoing treatment | Onset and evidence differ; they do not replace stabilization or urgent dialysis |
| Dialysis | Severe, refractory, recurrent, or otherwise clinically urgent hyperkalemia, especially with impaired kidney clearance | Requires timely access and specialist coordination; monitor for rebound |

Temporizing shifts do not eliminate total-body potassium. Plans for removal and repeated assessment are essential when ongoing production or impaired excretion persists \[1,4\].

## Assess urinary obstruction without delaying emergency care

Bladder assessment and catheterization are appropriate when retention or catheter malfunction is suspected. Decompression treats a reversible cause of obstructive kidney injury. A Foley catheter is not a universal first treatment for hyperkalemia, and there is no dependable fixed potassium reduction from catheter placement alone \[5\].

Do not postpone cardiac stabilization, shifting therapy, or urgent dialysis while waiting for urine output to improve. After decompression, monitor urine output, volume status, and electrolytes because post-obstructive diuresis can cause further disturbances \[5\].

## Reassess for response, hypoglycemia, and rebound

Repeat potassium at intervals appropriate to severity and treatment, monitor ECG and glucose as indicated, and evaluate ongoing potassium release and actual removal. An initial fall after insulin does not prove the emergency is over. Rebound may occur after the shift wears off or after dialysis \[1,4\].

Disposition depends on sustained response, the underlying cause, kidney function, and a safe monitoring plan. Do not use a calculator-generated expected reduction as evidence that a patient is ready for discharge.

## Apply the framework: a synthetic case

A patient with AKI has severe hyperkalemia, weakness, and ECG changes. A bladder scan also suggests retention. Explain why these findings require simultaneous emergency treatment and obstruction assessment, rather than “Foley first” followed by waiting several hours.

Clinical reasoning

The cardiac risk requires immediate monitored management. Calcium when indicated protects the myocardium; shifting agents provide temporary control; potassium removal and urgent nephrology assessment address persistent risk. Decompress confirmed retention and monitor its response without assuming that restored drainage guarantees adequate clearance. Continue serial potassium and glucose monitoring.

## References

1.  Lindner G, et al. Acute hyperkalemia in the emergency department: a summary from a KDIGO conference. 2020. [PubMed 32852924](https://pubmed.ncbi.nlm.nih.gov/32852924/)
2.  Clase CM, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a KDIGO Controversies Conference. 2020. [PubMed 31706619](https://pubmed.ncbi.nlm.nih.gov/31706619/)
3.  An Evidence-Based Narrative Review of the Emergency Department Management of Acute Hyperkalemia. 2021. [PubMed 33423833](https://pubmed.ncbi.nlm.nih.gov/33423833/)
4.  Hyperkalemia management in the emergency department: An expert panel consensus. 2021. [PubMed 34632453](https://pubmed.ncbi.nlm.nih.gov/34632453/)
5.  Yaxley J, Yaxley W. Obstructive uropathy — acute and chronic medical management. 2023. [PubMed 36704657](https://pubmed.ncbi.nlm.nih.gov/36704657/)


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/electrolytes/potassium/hyperkalemia.html) · Markdown synchronized October 3, 2026.


## Day 1 mechanism infographics — October 21, 2026

### Moving potassium is not removing potassium

Protect the heart, redistribute potassium, then remove the body load

[Full infographic, text companion and sources](https://urinenephrology.org/visual-reference/day1-potassium-compartments.html)

Calcium treats cardiac membrane instability; it does not reduce potassium concentration or body stores. Insulin and beta agonists redistribute potassium into cells. Follow glucose after insulin and reassess potassium and the ECG because redistribution wears off.